BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
2026 NewYorkCISO ORBIE Awards Recognize Greater New York’s Top Security Executives
Leading CISOs honored for leadership, enterprise security, and business impact at the NewYorkCISO ORBIE Awards on November 12, 2026, at the Ziegfeld Ballroom. NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The 2026 NewYorkCISO ORBIE Awards honored leading chief information security officers (CISOs) from Bristol Myers Squibb, Crum & Forster, CVS Health, RWJBarnabas Health, J. Crew, Vista Equity Partners, and Ballistic Ventures for their exceptional leadership. Hosted by NewYorkCISO, a chapter of the
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
2026 NewYorkCISO ORBIE Awards Recognize Greater New York’s Top Security Executives
Leading CISOs honored for leadership, enterprise security, and business impact at the NewYorkCISO ORBIE Awards on November 12, 2026, at the Ziegfeld Ballroom. NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The 2026 NewYorkCISO ORBIE Awards honored leading chief information security officers (CISOs) from Bristol Myers Squibb, Crum & Forster, CVS Health, RWJBarnabas Health, J. Crew, Vista Equity Partners, and Ballistic Ventures for their exceptional leadership. Hosted by NewYorkCISO, a chapter of the
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
How Investors Are Reacting To Bristol Myers Squibb (BMY) R&D Leadership Overhaul
Bristol Myers Squibb announced that Cristian Massacesi will lead a unified, end-to-end research and development organization from January 2027, with current research chief Robert Plenge staying in an advisory role through March 2027 to support the transition. Pulling discovery and clinical development into one structure could reshape how Bristol Myers Squibb allocates R&D resources, manages pipeline risk, and controls development costs across its broad portfolio. We will look at how Bristol...
5 Dividend Stocks With High Yields That Are Safer Than You Might Think
A high yield is a sign that investors are worried about a business, but sometimes that concern is overwrought.
How Many Shares of Pfizer, Merck or Bristol Myers Squibb Pay $1,000 a Month in Dividends?
Key TakeawaysAt today’s prices, $1,000 a month in dividends takes 6,977 Pfizer shares (about $201,600), 4,762 Bristol Myers Squibb shares (about $302,100) or 3,530 Merck shares (about $521,600). Pfizer’s 6.
3 Defensive Dividend Stocks for Retirees Worried About the Next Market Downturn
Phone plans, cancer drugs, and pipeline tolls keep getting paid when the economy stalls. Three low-beta dividend payers each carry one risk that could undercut the income, and only one of them is easy to spot.
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.
Bristol Myers Squibb is facing down the expiration of patent protections for older drugs, but new drugs are starting to show promise.
Agent 20 — SIR Price/Volume — buy
[not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-10-26 through 2026-11-12, BMY's PV path formed a tight cluster roughly between $60.57 and $63.13 on subdued volume (ranging 6.4M–10.3M, well below the 20-day ADV of 10.2M), with the notable exceptions of a brief spike on 2026-11-04 ($64.19, 14.1M) that failed to hold. Today, 2026-11-13, the stock closes at $63.43 — breaking above the dominant cluster range — on 15.2M shares, a volume z-score of +2.00 and nearly 50% above the 20-day ADV, signaling fresh demand absorbing the float. Reinforcing the read, the broader accumulation sub-path from 2026-10-29 through 2026-11-02 showed three consecutive UP days ($61.39→$62.48→$63.02) on robust volume (14.8M, 12.7M, 10.8M), establishing an up-and-right drift in 2-D PV space that today's bar now extends with confirming volume expansion. Risks: A failure to hold above the $62.00–$62.50 cluster floor on a subsequent high-volume down day would indicate distribution disguised as a breakout and would invalidate the cluster_break_up read. Additionally, the T10Y2Y at 0.24 (2.0σ below trend) signals a flattening yield curve that historically pressures defensive Health Care multiples, so any macro deterioration or renewed curve inversion could suppress follow-through buying over the 60–90 day horizon.
4 Healthcare Dividend Stocks for Retirees. One Yields Over 4%
A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that grows, and the gap between them is wider than it looks.
Agent 7 — Day Trader — decide: skip
BMY is up 2.09% intraday, a meaningful move suggesting real institutional flow. However, the evidence for continuation is mixed. No BMY-specific news catalyst is present in the headlines, which are unrelated to BMY (Merck, Pfizer, general finance). The macro context shows the yield curve (T10Y2Y at 0.24, 2.0σ below trend) in a bear-flattening posture, which tends to favor defensives like pharma — marginally supportive of the move. With only 60 minutes remaining until the forced close, there is limited time for further extension. The 2.09% move is already meaningful and may have absorbed much of the day's buying pressure. No reversal signals are evident, but no strong catalyst to drive a final-hour push either. With tight stops and bounded risk, the borderline read resolves to a slight continuation bias, but confidence is low.
Agent 7 — Day Trader — day_trade_skipped
BMY is up 2.09% intraday, a meaningful move suggesting real institutional flow. However, the evidence for continuation is mixed. No BMY-specific news catalyst is present in the headlines, which are unrelated to BMY (Merck, Pfizer, general finance). The macro context shows the yield curve (T10Y2Y at 0.24, 2.0σ below trend) in a bear-flattening posture, which tends to favor defensives like pharma — marginally supportive of the move. With only 60 minutes remaining until the forced close, there is limited time for further extension. The 2.09% move is already meaningful and may have absorbed much of the day's buying pressure. No reversal signals are evident, but no strong catalyst to drive a final-hour push either. With tight stops and bounded risk, the borderline read resolves to a slight continuation bias, but confidence is low.
What Will Decide Merck Stock Over The Next Six Months?
For questions about this article or underlying research, email help@trefis.com.
2026 NewYorkCISO ORBIE Awards Recognize Greater New York’s Top Security Executives
Leading CISOs honored for leadership, enterprise security, and business impact at the NewYorkCISO ORBIE Awards on November 12, 2026, at the Ziegfeld Ballroom. NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The 2026 NewYorkCISO ORBIE Awards honored leading chief information security officers (CISOs) from Bristol Myers Squibb, Crum & Forster, CVS Health, RWJBarnabas Health, J. Crew, Vista Equity Partners, and Ballistic Ventures for their exceptional leadership. Hosted by NewYorkCISO, a chapter of the
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% Run
Bristol-Myers Squibb has quietly turned in a strong share price run over the past few years, helped by fresh data for key therapies and a solid pipeline story. With the stock around US$62.91 at the last close, the real question for you is whether that level is backed up by the cash the business can generate over time. Over the past 3 years the stock has returned about 40.5%, which puts real pressure on the cash flow outlook to justify the step up in market value. Recent trial results for...
Is Amgen Stock Priced Right Against Its Peers?
For questions about this article or underlying research, email help@trefis.com.
BP or Bristol Myers Squibb: Only One Gets My Dividend Dollars for the Next 20 Years
Key TakeawaysBP yields 4. 7% and Bristol Myers Squibb yields 4.
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
What Sent Revolution Medicines Stock Lower?
For questions about this article or underlying research, email help@trefis.com.
REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
Replimune shares surge 80% as Tudriqev's commercial launch gains traction, earnings beat expectations and pipeline progress strengthens growth prospects.
Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer’s berobenatide through 2028 in exchange for milestone-based payments.
Bristol Myers Squibb Announces Evolution of Research & Development Organization
PRINCETON, N.J., November 12, 2026--Bristol Myers Squibb Announces Evolution of Research & Development Organization
Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare.
The stock is still attractive trading at 10 times forward earnings.
Bristol Myers Squibb Appoints Cristian Massacesi To Lead A Unified, End-To-End R&D Organization, Effective January 1, 2027
As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the company.Effective January 1, 2027,
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
Exelixis (NASDAQ:EXEL) is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event. Peters described the company as approaching a tr
A 72-Year-Old With $500,000 in PepsiCo, Nike and Bristol Myers Squibb Collects $1,729 a Month in Dividends. How Safe Is Each Check?
Key TakeawaysA hypothetical $500,000 portfolio split evenly across PepsiCo, Nike and Bristol Myers Squibb pays $20,519. 20 a year in dividends, or $1,709.
Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year
Pharmacy counters stay busy in every kind of market. Blood thinners, cancer drugs, and vaccines get refilled on schedule, and the companies that make them return part of those sales to shareholders as dividends. For retirees, that steady demand can become a steady paycheck. There’s a catch, and it’s called a patent cliff. A patent […]
Advanced Therapy Medicinal Products - Global Strategic Business Report: Capitalize on 11.8% CAGR to Secure $25.4B by 2030 as Novartis, Gilead, Bristol-Myers Squibb and Roche Compete
R&D investment, strategic partnerships, scalable manufacturing and expedited approvals unlock ATMP commercialization amid rising demand for personalized therapies.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Advanced Therapy Medicinal Products - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global Advanced Therapy Medicinal Products (ATMPs) market was valued at US$13 billion in 2024 and is projected to reach US$25.4 billion by 2030, expanding at a compo
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
Up 42% since January: Why Merck is defeating the patent cliff
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears
Exelixis (NASDAQ:EXEL) is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference discussion with Guggenheim biotech analyst Michael Schmidt. Peters described th
Can Gilead’s Cash Keep Growing?
For questions about this article or underlying research, email help@trefis.com.
$200,000 in Dividend Stocks: How a Roth IRA Could Save You $2,166 a Year
Six famous high-yield stocks pay the same income wherever you hold them, yet two of them quietly trigger most of the tax bill. Find out which two, and why the account you choose matters more than the stocks you pick.
Actinium-225 (Ac-225) Market Size, Share, Trends, Industry Analysis, and Global Forecast to 2036 | Targeted Alpha Therapy and Capacity Expansion Drive 30.5% CAGR Toward USD 1.20 Billion
Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Actinium-225 (Ac-225) Market Size, Share, and Industry Analysis - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering. The global Actinium-225 (Ac-225) market was valued at USD 62 million in 2025 and is estimated to reach USD 84.0 million in 2026. The market is projected to expand to USD 1.2 billion by 2036, representing a CAGR of 30.5% during the 2026-2036 forecast period. The report provides a comprehensive assessment of the A
Can You Still Buy Merck Stock Today?
For questions about this article or underlying research, email help@trefis.com.
While pharma peers stumble, AbbVie defeated the patent cliff
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Xenon Pharmaceuticals Q3 Earnings Call Highlights
Xenon Pharmaceuticals (NASDAQ:XENE) expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and advancing two pain treatments into midstage testing. On its third-quarter 2026 earnings call, the co
Bristol Myers Squibb (BMY) Reports 56 Week Pediatric Phase 3 Camzyos Data
Bristol-Myers Squibb (NYSE:BMY) reported new 56-week Phase 3 data for Camzyos in pediatric obstructive hypertrophic cardiomyopathy. The updated results show sustained efficacy over 56 weeks in children with symptomatic oHCM who were previously treated in shorter-term studies. Safety findings from the extended Phase 3 period were described as consistent with the known profile that supported the earlier pediatric approval. The fresh 56-week Camzyos data in pediatric oHCM tells only part of the...
5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income
Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names promise income, yet one of them runs coverage tighter than the rest. Which one deserves your trust?
Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?
Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.
MRK's 2027 Outlook Challenging, Long-Term Prospects Promising
Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential.
What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?
For questions about this article or underlying research, email help@trefis.com.
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027
Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.
Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
Bristol Myers Squibb has a 4% yield and a 55% payout ratio, which should greatly interest dividend lovers.
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?
Bristol Myers trades at under 10 times forward earnings, while Vertex commands nearly triple that multiple, but its margins are roughly double.
What Could Stall AbbVie Stock's Run?
For questions about this article or underlying research, email help@trefis.com.
Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
Bristol-Myers Squibb (BMY) said late Friday that 56-week results from its Phase 3 SCOUT-HCM clinical
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
PRINCETON, N.J., November 06, 2026--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos...
Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know which numbers actually matter before 2027 arrives.
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market
They are so much more than just dividend stocks.
Agent 7 — Day Trader — decide: skip
BMY is down ~2% intraday with no clear negative catalyst visible in the headlines — the morning news is a neuroscience AI alliance announcement, which is mildly positive or neutral. The absence of a negative headline driving the move suggests either sector rotation, broader market pressure, or quiet institutional selling. The macro context (elevated mortgage rates) is not directly relevant to BMY as a large-cap biopharma. With 360 minutes remaining (effectively most of the trading day still ahead), there is ample time for the move to continue or reverse. The ~2% move is at the lower bound of 'meaningful conviction' range, so it carries some momentum signal but is not a strong trending day. No reversal pattern is apparent from the data given. On balance, the momentum signal modestly favors continuation into the close, but the lack of a clear negative catalyst and the neutral-to-positive tone of available headlines prevent a high-confidence call. Assigning a slim continuation probability just above the threshold.
Agent 7 — Day Trader — day_trade_skipped
BMY is down ~2% intraday with no clear negative catalyst visible in the headlines — the morning news is a neuroscience AI alliance announcement, which is mildly positive or neutral. The absence of a negative headline driving the move suggests either sector rotation, broader market pressure, or quiet institutional selling. The macro context (elevated mortgage rates) is not directly relevant to BMY as a large-cap biopharma. With 360 minutes remaining (effectively most of the trading day still ahead), there is ample time for the move to continue or reverse. The ~2% move is at the lower bound of 'meaningful conviction' range, so it carries some momentum signal but is not a strong trending day. No reversal pattern is apparent from the data given. On balance, the momentum signal modestly favors continuation into the close, but the lack of a clear negative catalyst and the neutral-to-positive tone of available headlines prevent a high-confidence call. Assigning a slim continuation probability just above the threshold.
Agent 5 — Dip Buyer (Evolving) — pyramid
Pyramid add-on fired at +10.16% unrealized. Added 14 sh @ $62.43 ($874.02). Position now 43 sh @ weighted avg $58.55.
Agent 7 — Day Trader — decide: skip
BMY is up 3.34% intraday, a meaningful move indicating real institutional flow. However, the supporting news context is mixed at best — one article frames BMY as a value/dividend play ('dirt cheap, 4.2% yield') and another lists it as a stock to avoid, neither providing a clear catalyst that would drive sustained buying pressure into the close. The macro backdrop (2-year yields running 2σ above trend at 4.74%) creates a headwind for defensive pharma/dividend names as higher rates make yield-based equity stories less attractive. With 340 minutes remaining (essentially a full trading session still ahead), time is not a constraint, but the absence of a hard catalyst and the rate environment suggest some fade risk. The 3.34% move is itself meaningful evidence of real buyers with size, and momentum often persists at least partially, but without a clear fundamental driver visible this looks more like a technical squeeze or rotation play than a durable breakout. Leaning modestly toward continuation given the momentum signal and ample time, but not with high conviction.
Agent 7 — Day Trader — day_trade_skipped
BMY is up 3.34% intraday, a meaningful move indicating real institutional flow. However, the supporting news context is mixed at best — one article frames BMY as a value/dividend play ('dirt cheap, 4.2% yield') and another lists it as a stock to avoid, neither providing a clear catalyst that would drive sustained buying pressure into the close. The macro backdrop (2-year yields running 2σ above trend at 4.74%) creates a headwind for defensive pharma/dividend names as higher rates make yield-based equity stories less attractive. With 340 minutes remaining (essentially a full trading session still ahead), time is not a constraint, but the absence of a hard catalyst and the rate environment suggest some fade risk. The 3.34% move is itself meaningful evidence of real buyers with size, and momentum often persists at least partially, but without a clear fundamental driver visible this looks more like a technical squeeze or rotation play than a durable breakout. Leaning modestly toward continuation given the momentum signal and ample time, but not with high conviction.
Agent 7 — Day Trader — decide: skip
BMY is up 1.85% today, a meaningful move suggesting real buying flow. However, there is no clear catalyst headline driving the move — the headlines are generic (trending stock article, dividend stock mention, CIBC CDR launch unrelated to BMY). The macro context shows 5-year forward inflation at 1.5σ above trend, which modestly pressures rate-sensitive and dividend-oriented sectors like large-cap pharma, creating a mild headwind for continuation. With 295 minutes remaining there is ample time for a trade to play out, which is a positive factor. The move is below the 2% threshold where momentum becomes more compelling, and the absence of a specific catalyst means this could be broad sector rotation or index rebalancing flow that may or may not persist. No clear reversal signals are present. On balance, the setup is a modest lean toward continuation — ordinary momentum with no strong reason to fade — warranting a probability just above the 0.5 threshold.
Agent 7 — Day Trader — day_trade_skipped
BMY is up 1.85% today, a meaningful move suggesting real buying flow. However, there is no clear catalyst headline driving the move — the headlines are generic (trending stock article, dividend stock mention, CIBC CDR launch unrelated to BMY). The macro context shows 5-year forward inflation at 1.5σ above trend, which modestly pressures rate-sensitive and dividend-oriented sectors like large-cap pharma, creating a mild headwind for continuation. With 295 minutes remaining there is ample time for a trade to play out, which is a positive factor. The move is below the 2% threshold where momentum becomes more compelling, and the absence of a specific catalyst means this could be broad sector rotation or index rebalancing flow that may or may not persist. No clear reversal signals are present. On balance, the setup is a modest lean toward continuation — ordinary momentum with no strong reason to fade — warranting a probability just above the 0.5 threshold.
Agent 7 — Day Trader — decide: skip
BMY is down 1.80% today, which is a meaningful but not extreme move. However, several factors argue against continuation: (1) The most recent headline from 15:15 ET frames BMY as 'trading at a discount following its 38% run' — a bullish framing that suggests buy-the-dip narrative is forming, not momentum selling. (2) A second headline highlights two Phase 3 wins, providing fundamental support that could attract buyers into the close. These two headlines together create a narrative headwind against further downside. (3) With only 105 minutes remaining, there is limited time for momentum to extend. (4) The macro context (elevated T10Y3M, 1.6σ above trend) is modestly risk-negative but not specifically BMY-bearish — BMY is a defensive healthcare name that often benefits from risk-off rotation, which could actually provide a floor. (5) The move is -1.80%, just at the lower bound of the 'meaningful flow' range, and without a clear negative catalyst visible in recent news, this looks more like a technical or sector-rotation pullback than a conviction sell. On balance, the bullish framing in the most recent headlines and the defensive sector positioning give a real reason to expect fade rather than continuation — this is one of the cases where the probability falls below 0.5.
Agent 7 — Day Trader — day_trade_skipped
BMY is down 1.80% today, which is a meaningful but not extreme move. However, several factors argue against continuation: (1) The most recent headline from 15:15 ET frames BMY as 'trading at a discount following its 38% run' — a bullish framing that suggests buy-the-dip narrative is forming, not momentum selling. (2) A second headline highlights two Phase 3 wins, providing fundamental support that could attract buyers into the close. These two headlines together create a narrative headwind against further downside. (3) With only 105 minutes remaining, there is limited time for momentum to extend. (4) The macro context (elevated T10Y3M, 1.6σ above trend) is modestly risk-negative but not specifically BMY-bearish — BMY is a defensive healthcare name that often benefits from risk-off rotation, which could actually provide a floor. (5) The move is -1.80%, just at the lower bound of the 'meaningful flow' range, and without a clear negative catalyst visible in recent news, this looks more like a technical or sector-rotation pullback than a conviction sell. On balance, the bullish framing in the most recent headlines and the defensive sector positioning give a real reason to expect fade rather than continuation — this is one of the cases where the probability falls below 0.5.
Agent 7 — Day Trader — decide: skip
BMY is down 2.06% intraday, which is a meaningful move, but several factors push against continuation. First, the headline flow is notably positive/constructive: 'Two Phase 3 Wins' and 'Trades At A Discount Following 38% Run' suggest the news backdrop is supportive of the stock, not bearish — this creates counter-pressure that may attract dip buyers into the close. Second, with 190 minutes remaining there is ample time for a reversal, but the positive sentiment in headlines makes a fade of the down move more likely than further continuation. Third, the macro context (elevated T10Y3M, 1.6σ above trend) is mildly negative for risk assets broadly, but BMY as a defensive healthcare/biotech name is not highly rate-sensitive and could outperform. Fourth, after a 38% run, some profit-taking is understandable and may already be largely exhausted intraday. The combination of bullish news sentiment, potential dip-buying interest, and the stock's defensive characteristics create enough counter-pressure to keep continuation probability below 0.5. This does not meet the threshold to enter a short continuation trade.
Agent 7 — Day Trader — day_trade_skipped
BMY is down 2.06% intraday, which is a meaningful move, but several factors push against continuation. First, the headline flow is notably positive/constructive: 'Two Phase 3 Wins' and 'Trades At A Discount Following 38% Run' suggest the news backdrop is supportive of the stock, not bearish — this creates counter-pressure that may attract dip buyers into the close. Second, with 190 minutes remaining there is ample time for a reversal, but the positive sentiment in headlines makes a fade of the down move more likely than further continuation. Third, the macro context (elevated T10Y3M, 1.6σ above trend) is mildly negative for risk assets broadly, but BMY as a defensive healthcare/biotech name is not highly rate-sensitive and could outperform. Fourth, after a 38% run, some profit-taking is understandable and may already be largely exhausted intraday. The combination of bullish news sentiment, potential dip-buying interest, and the stock's defensive characteristics create enough counter-pressure to keep continuation probability below 0.5. This does not meet the threshold to enter a short continuation trade.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 7 — Day Trader — decide: skip
This is a clear reversal setup, not a continuation of the down move. BMY is currently down ~3.72% but the news catalyst is unambiguously positive: two Phase 3 wins announced this morning, with headlines confirming a 6.5% surge in BMY shares following the results. The current price of $56.92 vs a previous close of $59.12 suggests the stock likely gapped up on the positive trial data, then pulled back hard — possibly due to mixed read-through from the Contineum/IPF data confusion (Contineum initially dropped 25% on 'mixed' IPF data before BMY clarified the primary endpoint was met). The most recent headline at 13:33 confirms 'Bristol Myers Scores Two Phase 3 Wins' — the fundamental news remains positive. With 265 minutes remaining (well into the afternoon session), there is ample time for the market to re-price back toward the gap-up levels as the positive data narrative consolidates. The macro backdrop (elevated T10Y3M, 1.6σ above trend) is not particularly relevant to a pharma catalyst story. The setup reads as: positive catalyst, stock faded off morning highs due to confusion/profit-taking, but underlying news supports a mean-reversion bounce into the close. Direction call is UP (reversal from the intraday down move), with solid probability given the strong fundamental catalyst and time remaining.
Agent 7 — Day Trader — day_trade_skipped
This is a clear reversal setup, not a continuation of the down move. BMY is currently down ~3.72% but the news catalyst is unambiguously positive: two Phase 3 wins announced this morning, with headlines confirming a 6.5% surge in BMY shares following the results. The current price of $56.92 vs a previous close of $59.12 suggests the stock likely gapped up on the positive trial data, then pulled back hard — possibly due to mixed read-through from the Contineum/IPF data confusion (Contineum initially dropped 25% on 'mixed' IPF data before BMY clarified the primary endpoint was met). The most recent headline at 13:33 confirms 'Bristol Myers Scores Two Phase 3 Wins' — the fundamental news remains positive. With 265 minutes remaining (well into the afternoon session), there is ample time for the market to re-price back toward the gap-up levels as the positive data narrative consolidates. The macro backdrop (elevated T10Y3M, 1.6σ above trend) is not particularly relevant to a pharma catalyst story. The setup reads as: positive catalyst, stock faded off morning highs due to confusion/profit-taking, but underlying news supports a mean-reversion bounce into the close. Direction call is UP (reversal from the intraday down move), with solid probability given the strong fundamental catalyst and time remaining.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] BMY is down 16.1% from its 30-day high, qualifying as a meaningful mean-reversion candidate, and today's news is a strong positive catalyst: two Phase 3 wins (admilparant in IPF meeting primary endpoint, and RYZ101 in GEP-NETs interim success) driving a ~6.5% intraday surge, suggesting the prior selloff was sector/macro noise rather than fundamental deterioration. Options flow is modestly bullish (P/C ratio 0.70, call volume z=0.73) and the Health Care sector ranks 3rd of 11 by 30-day relative strength with positive 5-day flow, indicating no sector freefall. No recent SEC filings reveal guidance cuts or going-concern issues, and macro VIX at 15.41 (15th percentile) reflects a low-fear environment.
Agent 7 — Day Trader — decide: skip
This is a clear reversal setup, not a continuation of the down move. BMY is down ~2.1% today, but the news flow is strongly bullish: two Phase 3 trial successes announced this morning (ACTION-1 for RYZ101 in GEP-NETs and ALOFT-IPF for admilparant meeting primary endpoint), and a headline explicitly noting the stock 'surges' on these results at 11:36 ET. The current price of $57.88 versus the prior close of $59.12 suggests the stock may have gapped down early (perhaps on pre-market weakness or profit-taking from prior session) and is being bought back into positive clinical data. With 345 minutes remaining (nearly a full trading day still ahead), there is ample time for the positive clinical catalyst to reassert itself and drive price back toward or above prior close. The macro context (elevated T10Y3M) is marginally negative for the broader market but has limited direct bearing on a pharma name with company-specific catalysts of this magnitude. Two Phase 3 successes simultaneously is a high-conviction bullish event. Direction is UP (reversal of the down move), with solid continuation probability given the fundamental catalyst, time remaining, and typical pattern of clinical trial wins being absorbed over the full session.
Agent 7 — Day Trader — day_trade_skipped
This is a clear reversal setup, not a continuation of the down move. BMY is down ~2.1% today, but the news flow is strongly bullish: two Phase 3 trial successes announced this morning (ACTION-1 for RYZ101 in GEP-NETs and ALOFT-IPF for admilparant meeting primary endpoint), and a headline explicitly noting the stock 'surges' on these results at 11:36 ET. The current price of $57.88 versus the prior close of $59.12 suggests the stock may have gapped down early (perhaps on pre-market weakness or profit-taking from prior session) and is being bought back into positive clinical data. With 345 minutes remaining (nearly a full trading day still ahead), there is ample time for the positive clinical catalyst to reassert itself and drive price back toward or above prior close. The macro context (elevated T10Y3M) is marginally negative for the broader market but has limited direct bearing on a pharma name with company-specific catalysts of this magnitude. Two Phase 3 successes simultaneously is a high-conviction bullish event. Direction is UP (reversal of the down move), with solid continuation probability given the fundamental catalyst, time remaining, and typical pattern of clinical trial wins being absorbed over the full session.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
Agent 5 — Dip Buyer (Evolving) — decide: skip
BMY is down 13.7% from its 30-day high with no clear fundamental impairment — no 10-Q/8-K guidance cuts or going-concern language, and the drop appears sector-wide (Health Care underperforming SPY by 4.53pts over 30 days). Options flow is constructively bullish with call volume at a z-score of +1.60 and a low P/C ratio of 0.45, suggesting informed buyers are active on the dip. However, earnings are 24 days away (a meaningful headwind, -1 signal), a Leerink Partners downgrade to Market Perform with a $59 price target (essentially at current price) caps near-term upside, and the drop is just under the 15% mean-reversion threshold, limiting that positive signal. Net signal score: unusual call flow (+1), sector underperforming (+1), earnings in 15-30 days (-1), high 10Y yield neutral for value/defensive pharma (0), no cluster insider buys — netting roughly +1, a marginal case.
options_momentum closed long 100 @ $1.86 (-$48.43)
Stop: premium $1.86 ≤ trailing floor $2.35 (peak $3.13 × 0.75)
options_momentum opened long 100 @ $2.35
options_momentum closed long 200 @ $1.26 (-$125.96)
Stop: premium $1.26 ≤ trailing floor $1.42 (peak $1.89 × 0.75)
options_momentum opened long 200 @ $1.89
options_momentum closed long 500 @ $0.65 (-$343.51)
Stop: premium $0.65 ≤ trailing floor $1.16 (peak $1.55 × 0.75)
options_momentum opened long 500 @ $1.33